Similar articles

• Pitavastatin for the treatment of primary hyperlipidemia and mixed dyslipidemia.

  Gotto AM Jr, Moon J. Gotto AM Jr, et al. Expert Rev Cardiovasc Ther. 2010 Aug;8(8):1079-90. doi: 10.1586/erc.10.82. Expert Rev Cardiovasc Ther. 2010. PMID: 20670185 Review.
• Pitavastatin: a new HMG-CoA reductase inhibitor.

  Wensel TM, Waldrop BA, Wensel B. Wensel TM, et al. Ann Pharmacother. 2010 Mar;44(3):507-14. doi: 10.1345/aph.1M624. Epub 2010 Feb 23. Ann Pharmacother. 2010. PMID: 20179258 Review.
• Pitavastatin therapy in polymedicated patients is associated with a low risk of drug-drug interactions: analysis of real-world and phase 3 clinical trial data.

  Gosho M, Tanahashi M, Hounslow N, Teramoto T. Gosho M, et al. Int J Clin Pharmacol Ther. 2015 Aug;53(8):635-46. doi: 10.5414/CP202195. Int J Clin Pharmacol Ther. 2015. PMID: 26104032
• Pitavastatin magnesium (Zypitamag) for hyperlipidemia.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2018 Jun 18;60(1549):106. Med Lett Drugs Ther. 2018. PMID: 29913475 No abstract available.
• [How do I choose the best possible statin for my patient?].

  Viikari J. Viikari J. Duodecim. 2003;119(10):954-9. Duodecim. 2003. PMID: 12833785 Review. Finnish. No abstract available.